BIOMAT Database Logo BIOMAT Database Logo

Doxazosin in men with lower urinary tract symptoms: urodynamic evaluation at 15 months. 1997

G S Gerber, and B A Contreras, and G P Zagaja, and J H Kim, and G D Steinberg, and D B Rukstalis
Department of Surgery, University of Chicago Pritzker School of Medicine, Illinois, USA.

OBJECTIVE To assess the results of doxazosin treatment in men with lower urinary tract symptoms (LUTS) treated for 15 months and to correlate symptomatic changes with alterations in urodynamic measures. METHODS After an initial 3-month treatment period with doxazosin 4 mg/day, 50 men with LUTS were given the choice of continued treatment with this agent or other therapeutic options. All patients were evaluated by International Prostate Symptom Score (IPSS) questionnaires and urodynamic evaluation initially and after 3 months of treatment. Patients were followed for an additional 12 months and those who continued doxazosin treatment underwent repeat urodynamic testing. RESULTS Among the original 50 patients, 24 men (48%) continued doxazosin treatment for 15 months, 18 men (36%) discontinued therapy, and 8 men (16%) were either dead or lost to follow-up or had been diagnosed and treated for prostate cancer. Comparison of values at 3 and 15 months of follow-up (9.4 versus 13.4, P = 0.03) showed significant worsening of voiding symptoms, as assessed by the IPSS, in the 24 men still receiving doxazosin. This deterioration of subjective results with doxazosin occurred despite continued improvements in peak urinary flow rate (Qmax), detrusor pressure at peak flow (PdetQmax), and objective measures of obstruction (Abrams-Griffiths number) from 3 to 15 months of follow-up. CONCLUSIONS Relief of voiding symptoms in men with LUTS treated with doxazosin over prolonged intervals of 15 months does not correlate well with changes in urodynamic measures.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011470 Prostatic Hyperplasia Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both. Adenoma, Prostatic,Benign Prostatic Hyperplasia,Prostatic Adenoma,Prostatic Hyperplasia, Benign,Prostatic Hypertrophy,Prostatic Hypertrophy, Benign,Adenomas, Prostatic,Benign Prostatic Hyperplasias,Benign Prostatic Hypertrophy,Hyperplasia, Benign Prostatic,Hyperplasia, Prostatic,Hyperplasias, Benign Prostatic,Hypertrophies, Prostatic,Hypertrophy, Benign Prostatic,Hypertrophy, Prostatic,Prostatic Adenomas,Prostatic Hyperplasias, Benign,Prostatic Hypertrophies
D001748 Urinary Bladder Neck Obstruction Blocked urine flow through the bladder neck, the narrow internal urethral opening at the base of the URINARY BLADDER. Narrowing or strictures of the URETHRA can be congenital or acquired. It is often observed in males with enlarged PROSTATE glands. Bladder Neck Obstruction,Bladder Outlet Obstruction
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000317 Adrenergic alpha-Antagonists Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. Adrenergic alpha-Receptor Blockaders,alpha-Adrenergic Blocking Agents,alpha-Adrenergic Receptor Blockaders,alpha-Blockers, Adrenergic,Adrenergic alpha-Blockers,alpha-Adrenergic Antagonists,alpha-Adrenergic Blockers,Adrenergic alpha Antagonists,Adrenergic alpha Blockers,Adrenergic alpha Receptor Blockaders,Agents, alpha-Adrenergic Blocking,Antagonists, alpha-Adrenergic,Blockaders, Adrenergic alpha-Receptor,Blockaders, alpha-Adrenergic Receptor,Blockers, alpha-Adrenergic,Blocking Agents, alpha-Adrenergic,Receptor Blockaders, alpha-Adrenergic,alpha Adrenergic Antagonists,alpha Adrenergic Blockers,alpha Adrenergic Blocking Agents,alpha Adrenergic Receptor Blockaders,alpha Blockers, Adrenergic,alpha-Antagonists, Adrenergic,alpha-Receptor Blockaders, Adrenergic
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

G S Gerber, and B A Contreras, and G P Zagaja, and J H Kim, and G D Steinberg, and D B Rukstalis
Urodynamic findings in young men with chronic lower urinary tract symptoms.
November 2011, Neurourology and urodynamics,
G S Gerber, and B A Contreras, and G P Zagaja, and J H Kim, and G D Steinberg, and D B Rukstalis
Urodynamic studies in the evaluation of young men presenting with lower urinary tract symptoms.
May 2006, International journal of urology : official journal of the Japanese Urological Association,
G S Gerber, and B A Contreras, and G P Zagaja, and J H Kim, and G D Steinberg, and D B Rukstalis
Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings.
August 2001, The Journal of urology,
G S Gerber, and B A Contreras, and G P Zagaja, and J H Kim, and G D Steinberg, and D B Rukstalis
[Tonocardin (doxazosin) in treating lower urinary tract symptoms].
January 2003, Urologiia (Moscow, Russia : 1999),
G S Gerber, and B A Contreras, and G P Zagaja, and J H Kim, and G D Steinberg, and D B Rukstalis
Office evaluation of men with lower urinary tract symptoms.
November 1998, The Urologic clinics of North America,
G S Gerber, and B A Contreras, and G P Zagaja, and J H Kim, and G D Steinberg, and D B Rukstalis
New method for minimally invasive urodynamic assessment in men with lower urinary tract symptoms.
January 2008, Urology,
G S Gerber, and B A Contreras, and G P Zagaja, and J H Kim, and G D Steinberg, and D B Rukstalis
Urodynamic effects of doxazosin in men with lower urinary tract symptoms and benign prostatic obstruction. Results from three double-blind placebo-controlled studies.
January 1997, European urology,
G S Gerber, and B A Contreras, and G P Zagaja, and J H Kim, and G D Steinberg, and D B Rukstalis
Urodynamic evaluation in diabetic patients with prostate enlargement and lower urinary tract symptoms.
January 2008, Urologia internationalis,
G S Gerber, and B A Contreras, and G P Zagaja, and J H Kim, and G D Steinberg, and D B Rukstalis
Urodynamic risk factors of asymptomatic bacteriuria in men with non-neurogenic lower urinary tract symptoms.
December 2022, World journal of urology,
G S Gerber, and B A Contreras, and G P Zagaja, and J H Kim, and G D Steinberg, and D B Rukstalis
Urodynamic evaluation of patients with lower urinary tract symptoms and small prostate volume.
January 2008, Urologia internationalis,
Copied contents to your clipboard!